CeriBell, Inc.
CBLL
Positions held
Your positionsCBLL isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- CeriBell, Inc. operates in a growing medical devices market, which is expected to expand significantly due to increasing healthcare demands and technological advancements.
- Revenue increased by 6% compared to the prior quarter, reaching $28 million.
- Gross margin improved to 92.3%, up from 87.3% in the previous quarter.
- The company has a negative profit margin of approximately -64.7%, indicating ongoing financial challenges.
- Operating margin remains negative at -71.1%, reflecting difficulties in managing operational costs.
- Net income for the latest quarter was -19.268 million, continuing a trend of losses.
Fundamentals
| Market cap | $888.45M | Enterprise value | $781.10M | Trailing P/E | — | Forward P/E | -14.35 |
| PEG | — | Price / book | 6.90 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | 32.5% | Earnings growth | — | Gross margin | 88.9% | Operating margin | -71.1% |
| Profit margin | -64.7% | ROE | -43.9% | ROA | -23.4% | Debt / equity | 0.17 |
| Current ratio | 9.18 | Free cash flow | -$33.05M | Analyst recommendation | strong_buy | Mean target | $28.57 |
| 52w high | $25.63 | 52w low | $10.85 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $28.1M | $26.5M | $24.8M | $22.6M | $21.2M |
| Op margin | -71.1% | -78.3% | -58.9% | -64.8% | -70.5% |
| Net income | -$19.3M | -$19.7M | -$13.5M | -$13.5M | -$13.6M |
| Gross margin | 92.3% | 87.3% | 87.3% | 88.3% | 88.1% |
| Gross profit | $25.9M | $23.1M | $21.6M | $19.9M | $18.7M |
| Operating income | -$20.0M | -$20.7M | -$14.6M | -$14.6M | -$15.0M |
- Revenue +6% vs prior quarter ($28M vs $26M).
- Gross margin 92.3% (was 87.3% prior quarter).
- Operating margin expanded to -71.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $89.1M | $65.4M | $45.2M | $25.9M |
| Op margin | -65.6% | -60.7% | -66.4% | -139.0% |
| Net income | -$53.4M | -$40.5M | -$29.5M | -$37.2M |
| Gross margin | 87.9% | 86.7% | 84.4% | 82.9% |
| Gross profit | $78.3M | $56.8M | $38.2M | $21.5M |
| Operating income | -$58.4M | -$39.7M | -$30.0M | -$36.0M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-30 · CeriBell Receives FDA Clearance for Platform Software Update
2026-09-30 · Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis
2026-08-12 · CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push
2026-08-11 · CeriBell Inc (CBLL) (Q2 2026) Earnings Call Highlights: Revenue Accelerates 33% on Record ...
2026-08-11 · CeriBell, Inc. Q2 2026 Earnings Call Summary
2026-08-11 · CeriBell (CBLL) Q2 2026 Earnings Call Transcript
2026-08-10 · Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings
2026-08-10 · CeriBell Q2 Earnings Call Highlights
2026-08-10 · CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates
2026-08-10 · Ceribell Reports Second Quarter 2026 Financial Results
2026-08-10 · Ceribell Wins FDA Clearance for New AI Enhancements to Neurology Portal
2026-08-07 · What To Expect From CeriBell Inc (CBLL) Q2 2026 Earnings
Price (daily)
Full chart · RSI · MACD · patterns